Global Auto Injector Market


Global Auto Injector Market

 Category : Healthcare

 Published: May-2021
 Author: SPER Analyst

Press Release - The autoinjectors market is projected to be worth around USD 153.1 Billion by 2027

Rise in prevalence of chronic diseases and the corresponding need to medicate frequently, have led to an increase in demand for safe, self-administrable dosing options. Autoinjectors are considered among the leading product classes in this category.

Auto injectors are an effective mode of administration for intramuscular drugs. User friendly attributes of auto injectors reduce the burden of carrying conventional needles and syringes. However, limited awareness regarding proper use of auto injectors and high price of branded products are some of the important factors curbing the adoption of auto injector devices in emergency applications. 

Increasing innovations in materials and device functions of auto-injectors are driving the expansion of the auto injector market. Bayer HealthCare launched Betaconnect- an electronic auto injector for the treatment of relapsing-remitting multiple sclerosis (RRMS). This auto injector offers complete drug dosage for improved compliance and potentially reduce the overall cost. The SHL Group offers a variety of auto injectors that can accommodate changes in injections, such as larger volumes, high viscosity and others. The auto-injector manufacturers are focusing on improving the functionality of auto-injectors to improve disease management and treatment.

Click here to get a free sample report: 
Fierce competition in the auto injectors market due to the patient protection act has created an oligopolistic market environment. As a result, brands, such as EpiPen auto-injector, BD Physioject disposable auto injector, etc., have maintained their ranks in the market. However, recent patient expiration and increasing pressure from government bodies will led to reduction in auto injector prices and thus, reduce the profitability for branded manufacturers. Generic auto injectors are expected to present high growth opportunities for investors due to growing support from private insurance providers. Insurance services providers are dropping coverage on highly priced auto injectors and covering newly launched half priced generics. Overall revenue from pre-filled syringes is expected to grow during the forecast period due to rising need for targeted and sustained drug delivery. New entrants must comprehensively study the Auto Injectors market to penetrate and sustain in the price sensitive market. The study of the market scenario will provide insights about the business opportunities.

The global auto injector market by product type, therapy type, indication, route of distribution, end user, & regions. In terms of revenues, pre-filled auto injectors will hold substantial market share over the forecast period. On the contrary, the Fillable auto-injectors segment will exhibit limited investment opportunities, in terms of revenue, through 2027.

Some of the key companies operating in the auto injectors market, such as:
  • Sanofi
  • Pfizer Inc.
  • Becton
  • Dickinson and Company
  • Mylan N.V.
  • Novartis AG
  • Janssen Global Services LLC
  • Antares Pharma
  • Amgen Inc.
  • Bayer AG
  • Eli Lilly and Company.

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1 iso-1 ESOMAR
Secure Payments
SPER Payment Options
Contact HR

 [email protected]